New Risk • Jul 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.6m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$3.07m market cap). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding). Announcement • Jul 13
Azurity Pharmaceuticals, Inc. entered into the stock purchase agreement to acquire Matinas Biopharma Nanotechnologies, Inc. from Matinas BioPharma Holdings, Inc. (NYSEAM : MTNB) for $21 million. Azurity Pharmaceuticals, Inc. entered into the stock purchase agreement to acquire Matinas Biopharma Nanotechnologies, Inc. from Matinas BioPharma Holdings, Inc. (NYSEAM : MTNB) for $21 million on July 13, 2026.
The transaction is subject to the approval of Matinas stockholders and the satisfaction of customary closing conditions, including the satisfaction of the conditions to closing of the Business Combination with GH Power.
Steven M. Skolnick, Annie Nazarian Davydov of Lowenstein Sandler LLP acted as the legal advisor to Matinas BioPharma Holdings, Inc. Announcement • Jun 29
Matinas BioPharma Holdings, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance As previously disclosed, the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2026, Matinas BioPharma Holdings, Inc. (the Company) received a written notice (the April Notice) from the NYSE American LLC (the NYSE American) indicating that the Company was not in compliance with the NYSE American continued listing standard set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the Company Guide) requiring a company to have stockholders' equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The April Notice also indicated that the Company was not currently eligible for any exemption in Section 1003(a) of the Company Guide (including the exemption provided for companies with total value of market capitalization exceeding $50 million, among other things). On June 24, 2026, the Company received written notice (the June Notice) from the NYSE American that it is also not in compliance with the continued listing standard set forth in Section 1003(a)(ii) of the Company Guide, which requires a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The additional noncompliance was based on the Company's reported stockholders' equity of $3,022,000 as of March 31, 2026 and losses from continuing operations and/or net losses in five of its most recent fiscal years ended December 31, 2025. The Company submitted a plan (the Plan) to the NYSE American on May 4, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards. In the June Notice, the NYSE American also notified the Company that the Plan was accepted and that the NYSE American granted the Company a plan period through October 2, 2027 (the Plan Period, and such date, the Plan Period Deadline) to regain compliance with the continued listing standards. During the Plan Period, the Company will be subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(ii) and (iii) of the Company Guide during the Plan Period. If the Company does not regain compliance with the NYSE American listing standards by the Plan Period Deadline, or if the Company does not make progress consistent with the Plan during the Plan Period, then NYSE American staff may initiate delisting proceedings as appropriate. The June Notice has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded on the NYSE American during the Plan Period, subject to the Company's compliance with the other listing requirements of the NYSE American. The common stock will continue to trade under the symbol MTNB. The June Notice does not affect the Company's ongoing business operations or its reporting requirements with the Securities and Exchange Commission. 
